Latest Secondary Hyperparathyroidism (SHPT) News
The syndrome is more likely to develop in younger patients and those with higher preoperative ALP levels and lower preoperative calcium levels.
Benefits over placebo were demonstrated in 2 trials involving hemodialysis patients with moderate to severe secondary hyperparathyroidism.
Good results achieved with total parathyroidectomy without autotransplantation, according to researchers.
Researchers caution that radiofrequency ablation should only be considered for patients ineligible for parathyroid surgery.
Each 100 pg/mL increase in parathyroid hormone was associated with 2-fold increased odds of clotting.
In a study, calcitriol showed superior efficacy compared with alfacalcidol with respect to inhibiting parathyroid hormone secretion.
Increased fractional excretion of phosphate also found to increase risk of allograft loss.
Cure rate is significantly higher among patients who have intraoperative monitoring of intact parathyroid hormone level.
In a study, 94.1% of total PTx patients had improvement of bone mineral density at their most affected site.
Surgery decreased the risk of death from any cause by 32% compared with usual treatment.
Just 6.7% of patients had target levels of calcium, phosphorus, and parathyroid hormone a year after surgery.
More patients treated with MWA plus calcitriol reached iPTH levels below 150 pg/mL: 23.33% vs 8.54%.
Prior to starting therapy, parathyroid hormone trajectories show different patterns of increase and decrease.
Having 3 or 4 CKD-MBD markers in the danger zone more than doubled the chances of early death.
Calcitriol and paricalcitol raise levels of fibroblast growth factor 23 and sclerostin and lower levels of some bone turnover markers.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)